| Literature DB >> 8661826 |
W H Blahd1, C V Brown, S A Khonsary, J B Farahi, N Quinones, J Y Ribe, J J Coyle, E C Glass, M A Mandelkern.
Abstract
Positron emission tomography (PET) with fluorine-18-2-d-deoxyglucose (FDG) currently is being integrated into clinical oncology because it provides unique functional information that can be applied to the management of cancer. In particular, it is useful for assessing tumor activity and growth, evaluating efficacy of therapy, and detecting tumor recurrence. Studies have demonstrated the value of whole-body PET-FDG imaging when staging and managing abdominal malignancy.Entities:
Mesh：
Substances：
Year: 1996 PMID： 8661826 DOI： 10.1007/s002689900039
Source DB: PubMed Journal: World J Surg ISSN： 0364-2313 Impact factor: 3.352